Charles Schwab Investment Management Inc. Invests $2.23 Million in Upstream Bio, Inc. (NASDAQ:UPB)

Charles Schwab Investment Management Inc. acquired a new position in shares of Upstream Bio, Inc. (NASDAQ:UPB) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 135,323 shares of the company’s stock, valued at approximately $2,225,000.

Several other large investors also recently modified their holdings of UPB. US Bancorp DE acquired a new stake in Upstream Bio in the 4th quarter valued at about $27,000. Rhumbline Advisers acquired a new position in Upstream Bio in the 4th quarter worth $275,000. Bank of New York Mellon Corp acquired a new stake in shares of Upstream Bio in the fourth quarter valued at approximately $607,000. Finally, Moody Aldrich Partners LLC bought a new stake in Upstream Bio during the fourth quarter worth about $1,229,000.

Upstream Bio Stock Performance

NASDAQ UPB opened at $6.87 on Friday. Upstream Bio, Inc. has a 1 year low of $6.63 and a 1 year high of $29.46. The stock’s fifty day moving average price is $8.63.

About Upstream Bio

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.